CTVA vs KYTX
CTVA: Corteva is a global agriculture leader specializing in advanced seed technology and crop protection solutions to support sustainable farming. KYTX: Kyverna is a clinical-stage immunology biotech developing novel investigational therapeutics with no approved products and complete dependence on successful clinical trial outcomes.
Side-by-side fundamentals
| Metric | CTVA | KYTX | Edge |
|---|---|---|---|
| Price as of 2026-07-30 close | $89.34 | $7.49 | |
| Market cap as of 2026-07-31 | $60.1B | $430M | |
| P/E as of 2026-07-31 | 52.46 | n/a | |
| PEG as of 2026-07-31 | 3.98 | n/a | |
| Net margin as of 2026-07-31 | +6.5% | -411.3% | CTVA higher |
| Gross margin as of 2026-07-31 | +48.6% | n/a | |
| Operating margin as of 2026-07-31 | +15.0% | -418.3% | CTVA higher |
| ROE as of 2026-07-31 | +4.7% | -81.9% | CTVA higher |
| ROA as of 2026-07-31 | +2.7% | -64.9% | CTVA higher |
| Debt / equity as of 2026-07-31 | 0.14 | 0.13 | KYTX lower |
| Revenue growth (YoY) as of 2026-07-31 | +6.3% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -0.1% | n/a | |
| Dividend yield as of 2026-07-31 | +0.8% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-31 | 0.56 | 1.79 | |
| 1-year return as of 2026-07-30 close | +24.1% | +99.2% | KYTX higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-30.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.